ArticleFrontiers in neurology2026
Elevated peak width of skeletonized mean diffusivity in patients with end-stage kidney disease: evidence of diffuse white matter microstructural injury.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peak width of skeletonized mean diffusivity (PSMD) is a diffusion tensor imaging-based marker of diffuse white matter microstructural injury that has been associated with cerebral small vessel disease (CSVD). This study aimed to investigate whether patients with end-stage kidney disease (ESKD) exhibit altered PSMD compared with healthy controls. Methods: We prospectively enrolled 38 ESKD patients and 38 age- and sex-matched healthy controls. Diffusion tensor imaging (DTI) was performed using a three-tesla MRI scanner in patients with ESKD and healthy controls. We obtained PSMD based on DTI in several steps, including preprocessing, skeletonization, application of a custom mask, and histogram analysis. We compared PSMD between the groups and performed correlation analyses between PSMD and clinical factors. Results: PSMD was higher in patients with ESKD than in healthy controls (2.945 ± 0.361 vs. 2.552 ± 0.458 × 10 Conclusion: We demonstrated that patients with ESKD exhibited higher PSMD than healthy controls, suggesting diffuse white matter microstructural injury that may be related to CSVD. PSMD may be a useful imaging marker for characterizing diffuse white matter abnormalities in this population, although further studies incorporating conventional CSVD markers, vascular risk-matched controls, and clinical outcome measures are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.